Bart Heeg

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 16

Top Topics

Multiple Myeloma

Metastatic Colorectal Cancer

Top Venues

Journal of comparative effectiveness research

Leukemia & lymphoma

Journal of medical economics

Pharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Bart Heeg, Andre Verhoek, Gabriel Tremblay, Ofir Harari, Mohsen Soltanifar, Haitao Chu, Satrajit Roychoudhury, Joseph Christopher Cappelleri
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. Journal of comparative effectiveness research 12 (3) (2023)
Bart Heeg, Andre Verhoek, Gabriel Tremblay, Ofir Harari, Mohsen Soltanifar, Haitao Chu, Satrajit Roychoudhury, Joseph Christopher Cappelleri
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. Journal of comparative effectiveness research 12 (3) (2023)
Peter C Wigfield, Bart Heeg, Mario Ouwens
Improved estimation of overall survival and progression-free survival for state transition modeling. Journal of comparative effectiveness research 13 (1) (2023)
Bart Heeg, Andre Verhoek, Gabriel Tremblay, Ofir Harari, Mohsen Soltanifar, Haitao Chu, Satrajit Roychoudhury, Joseph Christopher Cappelleri
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. Journal of comparative effectiveness research (2023)
Peter C Wigfield, Bart Heeg, Mario Ouwens
Improved estimation of overall survival and progression-free survival for state transition modeling. Journal of comparative effectiveness research 13 (1) (2023)
Peter C Wigfield, Bart Heeg, Mario Ouwens
Improved estimation of overall survival and progression-free survival for state transition modeling. Journal of comparative effectiveness research 13 (1) (2023)
Peter C Wigfield, Bart Heeg, Mario Ouwens
Improved estimation of overall survival and progression-free survival for state transition modeling. Journal of comparative effectiveness research 13 (1) (2023)
Peter C Wigfield, Bart Heeg, Mario Ouwens
Improved estimation of overall survival and progression-free survival for state transition modeling. Journal of comparative effectiveness research 13 (1) (2023)
Ofir Harari, Mohsen Soltanifar, Andre Verhoek, Bart Heeg
Alone, together: On the benefits of Bayesian borrowing in a meta-analytic setting. Pharmaceutical statistics (2023)
Peter C Wigfield, Bart Heeg, Mario Ouwens
Improved estimation of overall survival and progression-free survival for state transition modeling. Journal of comparative effectiveness research (2023)
Bart Heeg, Andrea Garcia, Sophie van Beekhuizen, Andre Verhoek, Ilse van Oostrum, Satrajit Roychoudhury, Joseph Christopher Cappelleri, Maarten Jacobus Postma, Mario Johannes Nicolaas Martinus Ouwens
Novel and existing flexible survival methods for network meta-analyses. Journal of comparative effectiveness research (2022)
Yannan Hu, Majed Charaan, Ilse van Oostrum, Bart Heeg, Timothy Bell
The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada. Journal of medical economics 24 (1) (2021)
Sebastian Stintzing, Ilse van Oostrum, Chris P Pescott, Philippe Ronga, Bart Heeg, Volker Heinemann
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. Journal of medical economics 23 (5) (2020)
Meletios- Athanasios Dimopoulos, Michele Cavo, Maria-Victoria Mateos-Manteca, Thierry Facon, Bart Heeg, Sophie van Beekhuizen, Samron B Gebregergish, Sandhya Nair, Marta Pisini, Annette Lam, Mary Slavcev
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT). Leukemia & lymphoma 61 (3) (2019)
Maria-Victoria Mateos-Manteca, Jesús San F Miguel, Hartmut Goldschmidt, Pieter Sonneveld, Meletios- Athanasios Dimopoulos, Bart Heeg, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leukemia & lymphoma 61 (3) (2019)
Samron Brhane Gebregergish, Mahmoud Hashim, Bart Heeg, Thomas Wilke, Marco Rauland, Ulrike Hostalek
The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluations. Expert review of pharmacoeconomics & outcomes research 20 (2) (2019)